COHEN ALAIN J
Known title: DirectorCIK: 0001132946
Associated companies
Transaction History
| CCCC | ▲ Buy | Grant | 388 | $10K | 4/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 318 | $10K | 1/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 222 | $10K | 10/4/2021 | View on chart |
| CCCC | ▲ Buy | Grant | 388 | $10K | 4/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 318 | $10K | 1/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 222 | $10K | 10/4/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.